Diphtheria toxin fusion proteins.
Boston University Medical Center, MA 02118, USA.
F M
FM
Foss
M N
MN
Saleh
J G
JG
Krueger
J C
JC
Nichols
J R
JR
Murphy
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004167:Diphtheria Toxin / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D007376:Interleukin-2 / Q000737:chemistry / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D016399:Lymphoma, T-Cell / Q000628:therapy; D016410:Lymphoma, T-Cell, Cutaneous / Q000628:therapy; D011565:Psoriasis / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000627:therapeutic use
C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox